LEADER 04387nam 2200661Ia 450 001 9910808466903321 005 20240417005017.0 010 $a0-309-15368-9 010 $a1-282-64481-5 010 $a9786612644818 010 $a0-309-14629-1 035 $a(CKB)2670000000040029 035 $a(EBL)3378619 035 $a(SSID)ssj0000419516 035 $a(PQKBManifestationID)11327351 035 $a(PQKBTitleCode)TC0000419516 035 $a(PQKBWorkID)10383882 035 $a(PQKB)11533418 035 $a(Au-PeEL)EBL3378619 035 $a(CaPaEBR)ebr10395833 035 $a(CaONFJC)MIL264481 035 $a(OCoLC)648761504 035 $a(MiAaPQ)EBC3378619 035 $a(EXLCZ)992670000000040029 100 $a20100125d2010 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aHepatitis and liver cancer $ea national strategy for prevention and control of hepatitis B and C /$fHeather M. Colvin and Abigail E. Mitchell, editors; Committee on the Prevention and Control of Viral Hepatitis Infections, Board on Population Health and Public Health Practice 205 $a1st ed. 210 $aWashington, DC $cNational Academies Press$dc2010 215 $a1 online resource (253 p.) 300 $aDescription based upon print version of record. 311 $a0-309-14628-3 320 $aIncludes bibliographical references and index. 327 $a""Front Matter""; ""Reviewers""; ""Acknowledgments""; ""Contents""; ""Acronyms and Abbreviations""; ""Summary""; ""1 Introduction""; ""2 Surveillance""; ""3 Knowledge and Awareness About Chronic Hepatitis B and Hepatitis C""; ""4 Immunization""; ""5 Viral Hepatitis Services""; ""Appendix A: Committee Biographies""; ""Appendix B: Public Meeting Agendas""; ""Index"" 330 $a"The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations."--Publisher's description. 606 $aHepatitis B$zUnited States 606 $aHepatitis C$zUnited States 606 $aLiver$xCancer$zUnited States 615 0$aHepatitis B 615 0$aHepatitis C 615 0$aLiver$xCancer 676 $a616.99/436 701 $aColvin$b Heather M$01608634 701 $aMitchell$b Abigail E$01608635 712 02$aInstitute of Medicine (U.S.).$bCommittee on the Prevention and Control of Viral Hepatitis Infections. 712 02$aInstitute of Medicine (U.S.).$bBoard on Population Health and Public Health Practice. 712 02$aNational Academies Press (U.S.) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910808466903321 996 $aHepatitis and liver cancer$93935487 997 $aUNINA